Aptosyn exisulind: Phase II/III

Cell Pathways Inc. (CLPA), Horsham, Penn.
Product: Aptosyn exisulind
Business: Cancer
Therapeutic category: Apoptosis
Target: cGMP-PDE
Description: Oral sulfone metabolite of

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE